HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
Archive

All News

Every briefing, headline, and filing we've published, newest first.

PipelinePharmaVoice ↗
Dr. Ebrahim Delpassand, founder and CEO of RadioMedix, played a pivotal role in advancing nuclear medicine as …
Apr 9, 2026
List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)
NegotiationsDrug Channels ↗
This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Upd…
Apr 8, 2026
PolicyDrug Channels ↗
This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Upd…
Apr 8, 2026
The WeekDrug Channels ↗
Today’s guest post comes from Chrissy Hand, Chief Product and Commercial Officer at CoverMyMeds. Chrissy highl…
Apr 2, 2026
The WeekDrug Channels ↗
Spring is here in always-sunny Philadelphia. The vernal equinox has brought us an unexpected bounty of notewor…
Mar 31, 2026
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments
DataDrug Channels ↗
Three is still the magic number for pharmacy benefit managers (PBMs). For 2025, 80% of all equivalent prescrip…
Mar 30, 2026
Rinvoq Biosimilar Race: Launch Timeline, Pricing Floor, and Who Files First Ahead of 2033
AbbVie's $5.9B JAK1 inhibitor is the next Humira — and the biosimilar pipeline is already forming seven years …
Mar 27, 2026
The WeekDrug Channels ↗
We had an absolutely incredible time at the second annual Drug Channels Leadership Forum (DCLF)! Despite some …
Mar 25, 2026
Exa-cel (Casgevy) Price Breakdown: What the $2.2M Sticker Actually Covers in 2026
The list price grabs the headline. The cost of care is closer to $3M — and Medicaid is on the hook for most of…
Mar 11, 2026
← Newer Page 32
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.